Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional tranexamic acid vs topical fluocinolone acetonide for macular amyloidosis
IRCT20191104045328N38Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jul 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tranexamic acid and fluocinolone in Macular Amyloidosis (2 arms), sponsored by Arak University of Medical Sciences. Started Jul 2025; status: completed.
02
Drugs
tranexamic acidfluocinolone
03
Conditions
Macular Amyloidosis
Beyond the preview
Go deeper on IRCT20191104045328N38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N38.